Results 31 to 40 of about 181,580 (299)

Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration

BMC Ophthalmology, 2020
Background To evaluate the three-year outcome after intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD). Methods Forty-nine treatment-naïve nAMD patients (50 eyes) were enrolled in this prospective study.
Kanako Itagaki, Tetsuju Sekiryu, Akihito Kasai, Yukinori Sugano, Masashi Ogasawara, Masaaki Saito   +5 more
doaj   +1 more source

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Ophthalmology and Therapy, 2020
Aims To report the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and reading performance (reading acuity and maximum reading speed (MRS) using the MNREAD test) between baseline and 24 months in ...
Praveen J. Patel, Hari Jayaram, Maria Eleftheriadou, Clara Vazquez-Alfageme, Niaz Islam, Gary S. Rubin, Bishwanath Pal, Peter K. Addison, Robin Hamilton, Simona Degli Esposti   +9 more
doaj   +1 more source

24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting

BMC Ophthalmology, 2017
Background To evaluate the clinical effectiveness and analyze the outcomes of a treat-and-extend (T&E) treatment regimen with ranibizumab for wet age-related macular degeneration (ARMD) in real life clinical settings over the first 2 years (24 months) of
Athanasios Vardarinos, Nitin Gupta, Raazia Janjua, Abigail Iron, Theo Empeslidis, Konstantinos T. Tsaousis   +5 more
doaj   +1 more source

Treat-and-Extend Intravitreal Bevacizumab for Branch Retinal Vein Occlusion

Ophthalmic Surgery, Lasers and Imaging Retina, 2014
BACKGROUND AND OBJECTIVE: To determine the effectiveness and direct medical costs of treat-and-extend (TAE) intravitreal bevacizumab (IVB) for the treatment of branch retinal vein occlusion (BRVO)–associated macular edema (ME). PATIENTS AND METHODS: Retrospective chart review of 52 ...
Rush, R, Simunovic, M, Aragon, A, Ysasaga, J   +3 more
openaire   +3 more sources

One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy

Ophthalmology and Therapy, 2020
Introduction To evaluate 1-year outcomes of intravitreal aflibercept (IVA) using a treat-and-extend (TAE) regimen for polypoidal choroidal vasculopathy (PCV) and identify the factors for patients whose treatment intervals could be extended. Methods Fifty-
Tomoko Tamachi, Takeya Kohno, Manabu Yamamoto, Kumiko Hirayama, Akika Kyo, Nobuhiko Ueda, Michiko Hirabayashi, Kunihiko Shiraki, Shigeru Honda   +8 more
doaj   +1 more source

Adenine base editing to treat progeria syndrome and extend the lifespan

The Journal of Cardiovascular Aging, 2021
Hutchinson-Gilford progeria syndrome (HGPS) is an exceedingly rare and hitherto incurable and fatal disease marked by accelerated aging simultaneously affecting a number of organs. Most cases of HGPS are caused by a single copy of a specific single-nucleotide mutation, c.C1824T, in the LMNA (lamin A) gene.
openaire   +3 more sources

Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study

International Journal of Retina and Vitreous, 2019
Background To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlusions (CRVOs)
Rahul N. Khurana, Louis K. Chang, Alok S. Bansal, James D. Palmer, Chengqing Wu, Mark R. Wieland   +5 more
doaj   +1 more source

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy

Clinical Ophthalmology, 2023
Tomoko Miyakubo, Ryo Mukai, Hidetaka Matsumoto, Masahiro Morimoto, Maki Takahashi, Kazuki Nagai, Kosuke Nakamura, Junki Hoshino, Hideo Akiyama Department of Ophthalmology, Gunma University, Graduate School of Medicine, Maebashi, Gunma ...
Miyakubo T, Mukai R, Matsumoto H, Morimoto M, Takahashi M, Nagai K, Nakamura K, Hoshino J, Akiyama H   +8 more
doaj  

Real-Life Evidence for Using a Treat-and-Extend Injection Regime for Patients with Central Retinal Vein Occlusion

Ophthalmology and Therapy, 2019
Introduction To report the 52-week treatment outcomes with intravitreal injections of aflibercept using a treat-and-extend regimen for treating macular edema secondary to central retinal vein occlusion (CRVO). Methods A retrospective analysis of patients
Maria Eleftheriadou, Luke Nicholson, Giulia D’Alonzo, Peter K. F. Addison   +3 more
doaj   +1 more source

Age, Initial Central Retinal Thickness, and OCT Biomarkers Have an Influence on the Outcome of Diabetic Macular Edema Treated With Ranibizumab– Tri-center 12-Month Treat-and-Extend Study

Frontiers in Medicine, 2021
Objective: We report the tri-center 1-year outcomes of a treat-and-extend (T&E) regimen in four-week intervals with ranibizumab for diabetic macular edema (DME).Methods: In this retrospective study, all eyes received 3 monthly loading injections of 0.
Chun-Ting Lai, Yi-Ting Hsieh, Chun-Ju Lin, Chun-Ju Lin, Chun-Ju Lin, Jia-Kang Wang, Jia-Kang Wang, Chih-Ying Lin, Chih-Ying Lin, Ning-Yi Hsia, Ning-Yi Hsia, Henry Bair, Huan-Sheng Chen, Chiung-Yi Chiu, Shao-Wei Weng   +14 more
doaj   +1 more source